{"id":"ribavirin-pre-treatment","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Hemolytic anemia"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Nausea"},{"rate":null,"effect":"Teratogenicity/reproductive toxicity"},{"rate":"5-10","effect":"Hyperuricemia"}]},"_chembl":{"chemblId":"CHEMBL1643","moleculeType":"Small molecule","molecularWeight":"244.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ribavirin is a broad-spectrum antiviral agent that acts as a guanosine analog, depleting intracellular guanosine triphosphate pools and directly inhibiting viral RNA polymerases. When used as pre-treatment, it aims to establish antiviral activity prior to primary therapeutic intervention, particularly in chronic hepatitis C virus infection where it enhances sustained virological response rates when combined with interferon-based regimens.","oneSentence":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate metabolism and RNA-dependent RNA polymerase activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:05:01.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (pre-treatment prior to interferon-based therapy)"},{"name":"Respiratory syncytial virus infection (off-label use)"}]},"trialDetails":[{"nctId":"NCT03655561","phase":"","title":"Lassa Fever Clinical Course and Prognostic Factors in Nigeria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for International Medical Action","startDate":"2018-04-05","conditions":"Lassa Fever, Lassa Virus Infection, Pregnancy Complications","enrollment":1200},{"nctId":"NCT02613403","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-10","conditions":"Hepatitis, Hepatitis C, Digestive System Diseases","enrollment":94},{"nctId":"NCT00882193","phase":"EARLY_PHASE1","title":"Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-05-01","conditions":"Chronic Hepatitis C, Genotype 1, Relapse","enrollment":2},{"nctId":"NCT03537196","phase":"PHASE4","title":"DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-11-13","conditions":"Hepatitis C, Drug Use, Viral Hepatitis C","enrollment":979},{"nctId":"NCT03067129","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-20","conditions":"Hepatitis C Virus (HCV)","enrollment":129},{"nctId":"NCT02087111","phase":"PHASE4","title":"Telaprevir in Genotype 3 HCV","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-04","conditions":"Hepatitis C","enrollment":14},{"nctId":"NCT05532306","phase":"PHASE1","title":"Bioequivalence Study of Ribavirin in Healthy Adult Subjects Under Fed Condition","status":"COMPLETED","sponsor":"Future University in Egypt","startDate":"2020-10-11","conditions":"Healthy Subjects","enrollment":36},{"nctId":"NCT02939989","phase":"PHASE3","title":"Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-11-21","conditions":"Hepatitis C Virus Infection","enrollment":33},{"nctId":"NCT03512210","phase":"PHASE4","title":"Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2018-10-22","conditions":"Hepatitis C, HIV-1-infection, Liver Diseases","enrollment":400},{"nctId":"NCT03365635","phase":"PHASE4","title":"Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-09-22","conditions":"Hepatitis C, Hemodialysis, Nosocomial Infection","enrollment":6},{"nctId":"NCT01185028","phase":"PHASE1, PHASE2","title":"A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2010-08","conditions":"Hepatitis C Infection, HIV Infection","enrollment":8},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT00945880","phase":"PHASE1","title":"Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2009-07","conditions":"Hepatitis C","enrollment":12},{"nctId":"NCT00758043","phase":"PHASE3","title":"A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2008-10","conditions":"Hepatitis C","enrollment":540},{"nctId":"NCT01425203","phase":"PHASE3","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-23","conditions":"Chronic Hepatitis C Genotype 1","enrollment":238},{"nctId":"NCT02105701","phase":"PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-05","conditions":"Hepatitis C Infection","enrollment":420},{"nctId":"NCT01080222","phase":"PHASE2","title":"A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2010-08","conditions":"Chronic Hepatitis C Virus Infection","enrollment":152},{"nctId":"NCT00237484","phase":"PHASE3","title":"Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07-18","conditions":"Hepatitis C, Chronic","enrollment":89},{"nctId":"NCT00166296","phase":"PHASE2","title":"Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-03","conditions":"Major Depressive Disorder, Hepatitis C, Chronic","enrollment":133},{"nctId":"NCT01741545","phase":"PHASE3","title":"Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03-31","conditions":"Hepatitis C Virus","enrollment":71},{"nctId":"NCT02293941","phase":"PHASE2","title":"Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies","status":"TERMINATED","sponsor":"TaiwanJ Pharmaceuticals Co., Ltd","startDate":"2014-05","conditions":"Chronic Hepatitis C","enrollment":54},{"nctId":"NCT04457050","phase":"PHASE4","title":"Effect of Hepatitis C Clearance on Insulin Resistance","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2017-10-30","conditions":"Insulin Resistance, Hepatitis C","enrollment":160},{"nctId":"NCT04391985","phase":"PHASE1, PHASE2","title":"Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":113},{"nctId":"NCT04374071","phase":"","title":"Early Short Course Corticosteroids in COVID-19","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2020-03-12","conditions":"COVID, Pneumonia, Viral","enrollment":250},{"nctId":"NCT02249182","phase":"PHASE2","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-11-05","conditions":"Hepatitis C Virus Infection","enrollment":226},{"nctId":"NCT00718172","phase":"PHASE1","title":"Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2008-07-11","conditions":"Hepatitis C, Chronic","enrollment":81},{"nctId":"NCT01821625","phase":"PHASE2, PHASE3","title":"Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-04","conditions":"Thrombocytopenia, Hepatitis C","enrollment":7},{"nctId":"NCT00230854","phase":"PHASE1","title":"Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2005-08","conditions":"Chronic Hepatitis C, Hepatitis, Viral, Human","enrollment":28},{"nctId":"NCT04071353","phase":"","title":"Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2019-08-01","conditions":"Chronic Hepatitis C","enrollment":1000},{"nctId":"NCT01598090","phase":"PHASE3","title":"Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-14","conditions":"Hepatitis C Virus","enrollment":881},{"nctId":"NCT02636608","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-27","conditions":"Chronic Hepatitis C","enrollment":244},{"nctId":"NCT02618928","phase":"","title":"The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-15","conditions":"Chronic Hepatitis C","enrollment":735},{"nctId":"NCT02817594","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-01-20","conditions":"Chronic Hepatitis C","enrollment":51},{"nctId":"NCT03053180","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-20","conditions":"Chronic Hepatitis C","enrollment":60},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT02807402","phase":"","title":"Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-14","conditions":"Chronic Hepatitis C","enrollment":522},{"nctId":"NCT01938625","phase":"PHASE2","title":"A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2013-12-12","conditions":"Hepatitis C, Chronic","enrollment":35},{"nctId":"NCT01987453","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"HCV Infection","enrollment":100},{"nctId":"NCT02600351","phase":"PHASE3","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"Hepatitis C Virus Infection","enrollment":87},{"nctId":"NCT01726517","phase":"PHASE2","title":"Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-10","conditions":"Chronic Hepatitis C Virus","enrollment":100},{"nctId":"NCT02300103","phase":"PHASE2","title":"Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-01","conditions":"Hepatitis C Virus Infection","enrollment":69},{"nctId":"NCT02640547","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-26","conditions":"Chronic Hepatitis C","enrollment":394},{"nctId":"NCT00665353","phase":"PHASE2","title":"Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-03","conditions":"HIV-1 and Hepatitis C Co-Infection","enrollment":19},{"nctId":"NCT02358044","phase":"PHASE3","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-27","conditions":"Hepatitis C","enrollment":257},{"nctId":"NCT02105454","phase":"PHASE2","title":"Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-23","conditions":"Hepatitis C Virus","enrollment":79},{"nctId":"NCT01390844","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-21","conditions":"Hepatitis C, Chronic","enrollment":282},{"nctId":"NCT02785666","phase":"PHASE3","title":"Swiss HCVree Trial","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2016-06","conditions":"Hepatitis C, HIV","enrollment":150},{"nctId":"NCT01945294","phase":"PHASE3","title":"Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-10","conditions":"Hepatitis C, Chronic","enrollment":257},{"nctId":"NCT01854528","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-06","conditions":"Chronic Hepatitis C Infection","enrollment":148},{"nctId":"NCT01854697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":311},{"nctId":"NCT02605304","phase":"PHASE2","title":"12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2016-02-17","conditions":"HIV-1 Infection, Hepatitis C","enrollment":7},{"nctId":"NCT03067883","phase":"PHASE2","title":"Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2016-11-09","conditions":"Chronic Hepatitis c","enrollment":40},{"nctId":"NCT02504099","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-07","conditions":"Chronic Hepatitis C Infection","enrollment":3},{"nctId":"NCT01782495","phase":"PHASE2","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-02-25","conditions":"Chronic Hepatitis C Infection","enrollment":129},{"nctId":"NCT02446717","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04","conditions":"Chronic Hepatitis C, Hepatitis C Virus, HCV","enrollment":141},{"nctId":"NCT03268317","phase":"","title":"Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-01","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT03241823","phase":"","title":"Assessment of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs.","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-12-01","conditions":"Hepatitis C, Liver Cirrhosis","enrollment":100},{"nctId":"NCT01962441","phase":"PHASE3","title":"SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09-24","conditions":"Hepatitis C","enrollment":601},{"nctId":"NCT00239733","phase":"PHASE4","title":"Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-03","conditions":"Thrombocytopenia, Hepatitis C, HIV Infections","enrollment":6},{"nctId":"NCT01482390","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-30","conditions":"Hepatitis C","enrollment":80},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00845065","phase":"PHASE3","title":"Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02","conditions":"Hepatitis C, Chronic","enrollment":202},{"nctId":"NCT00202839","phase":"PHASE4","title":"Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic","enrollment":160},{"nctId":"NCT01743521","phase":"PHASE4","title":"DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2013-01","conditions":"Hepatitis C, Chronic","enrollment":14},{"nctId":"NCT01628692","phase":"PHASE2","title":"Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07","conditions":"Hepatitis C Virus","enrollment":230},{"nctId":"NCT01888900","phase":"PHASE2","title":"New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2013-05","conditions":"Cirrhosis, Chronic Hepatitis C, Hepatitis C","enrollment":35},{"nctId":"NCT02319031","phase":"PHASE3","title":"Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-02","conditions":"Hepatitis C","enrollment":53},{"nctId":"NCT00927290","phase":"PHASE3","title":"Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance","status":"TERMINATED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-12-03","conditions":"Chronic Hepatitis C, Insulin Resistance","enrollment":40},{"nctId":"NCT01579019","phase":"PHASE2","title":"A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2012-07","conditions":"Hepatitis C, Chronic","enrollment":""},{"nctId":"NCT01358864","phase":"PHASE3","title":"Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-06","conditions":"Hepatitis C, Chronic","enrollment":678},{"nctId":"NCT02716779","phase":"PHASE2","title":"Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-04","conditions":"Hepatitis C, Chronic","enrollment":68},{"nctId":"NCT01482403","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11","conditions":"Hepatitis C, Chronic","enrollment":58},{"nctId":"NCT01483742","phase":"PHASE2","title":"A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-04","conditions":"Hepatitis C, Chronic","enrollment":43},{"nctId":"NCT01701063","phase":"PHASE1, PHASE2","title":"An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-01","conditions":"Hepatitis C","enrollment":42},{"nctId":"NCT01330316","phase":"PHASE3","title":"A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-07","conditions":"Hepatitis C","enrollment":119},{"nctId":"NCT01525628","phase":"PHASE1","title":"Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-04","conditions":"Hepatitis C, Chronic","enrollment":72},{"nctId":"NCT00747539","phase":"","title":"Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2008-07","conditions":"HIV, Hepatitis C, Infections","enrollment":330},{"nctId":"NCT01485991","phase":"PHASE3","title":"TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-02","conditions":"Hepatitis C","enrollment":771},{"nctId":"NCT00854802","phase":"NA","title":"A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2009-01","conditions":"Chronic Hepatitis C","enrollment":290},{"nctId":"NCT01724086","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-10","conditions":"Chronic Hepatitis C","enrollment":90},{"nctId":"NCT00723645","phase":"","title":"Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-04","conditions":"Hepatitis C, Chronic","enrollment":279},{"nctId":"NCT01625338","phase":"PHASE3","title":"Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-06","conditions":"Chronic Hepatitis C","enrollment":534},{"nctId":"NCT00724464","phase":"","title":"Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":332},{"nctId":"NCT02204475","phase":"PHASE3","title":"Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-11","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT01170962","phase":"PHASE2","title":"Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-08","conditions":"Hepatitis C Virus","enrollment":512},{"nctId":"NCT01718158","phase":"PHASE3","title":"Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-01","conditions":"Hepatitis C","enrollment":444},{"nctId":"NCT01012895","phase":"PHASE2","title":"Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Chronic Hepatitis C","enrollment":215},{"nctId":"NCT00724373","phase":"","title":"Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11","conditions":"Hepatitis C, Chronic","enrollment":442},{"nctId":"NCT01641666","phase":"PHASE3","title":"Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT01467492","phase":"PHASE4","title":"Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-01","conditions":"Hepatitis C","enrollment":121},{"nctId":"NCT01508286","phase":"","title":"Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects","status":"NO_LONGER_AVAILABLE","sponsor":"Janssen-Cilag International NV","startDate":"","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT00856024","phase":"","title":"ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07","conditions":"Hepatitis C, Chronic","enrollment":902},{"nctId":"NCT01465516","phase":"","title":"Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir","status":"TERMINATED","sponsor":"Arrowhead Regional Medical Center","startDate":"2011-11","conditions":"Hepatitis C Infection","enrollment":105},{"nctId":"NCT00993122","phase":"PHASE4","title":"Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2009-10","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT02469012","phase":"NA","title":"Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy","status":"UNKNOWN","sponsor":"University of Wuerzburg","startDate":"2014-10","conditions":"Hepatitis C, Chronic","enrollment":30},{"nctId":"NCT01459913","phase":"PHASE3","title":"Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2011-11","conditions":"Hepatitis C, Chronic","enrollment":239},{"nctId":"NCT01466790","phase":"PHASE2","title":"A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-01","conditions":"Hepatitis C","enrollment":168},{"nctId":"NCT01498068","phase":"PHASE3","title":"Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-01","conditions":"Genotype 1 Chronic Hepatitis C","enrollment":36},{"nctId":"NCT02339337","phase":"PHASE4","title":"A Pilot Study To Evaluate the Efficacy of Response Guided Therapy of Peginterferon Alfa Plus Ribavirin in the Treatment of Patients With HCV/HBV Co-Infection","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2010-06","conditions":"HBV/HCV Co-infection","enrollment":203},{"nctId":"NCT01260350","phase":"PHASE2","title":"Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-12","conditions":"Chronic Hepatitis C Infection","enrollment":292}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ribavirin pre treatment","ribavirin priming","Recurrence of hepatitis c","hepatitis c","transplanted patients"],"phase":"marketed","status":"active","brandName":"ribavirin pre-treatment","genericName":"ribavirin pre-treatment","companyName":"University of Roma La Sapienza","companyId":"university-of-roma-la-sapienza","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate metabolism and RNA-dependent RNA polymerase activity. Used for Chronic hepatitis C virus infection (pre-treatment prior to interferon-based therapy), Respiratory syncytial virus infection (off-label use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}